Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines.
Acute lymphoblastic leukaemia
Cytarabine
Cytostatics
Dexamethasone
Drug combinations
Idelalisib
PIK3-inhibition
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
09
2019
accepted:
16
07
2020
entrez:
21
8
2020
pubmed:
21
8
2020
medline:
21
8
2020
Statut:
epublish
Résumé
The introduction of combined conventional cytostatics and pathway-specific inhibitors has opened new treatment options for several cancer types including hematologic neoplasia such as leukaemias. As the detailed understanding of the combination-induced molecular effects is often lacking, the identification of combination-induced molecular mechanisms bears significant value for the further development of interventional approaches. Combined application of conventional cytostatic agents (cytarabine and dexamethasone) with the PI3K-inhibitor Idelalisib was analysed on cell-biologic parameters in two acute pro-B lymphoblastic leukaemia (B-ALL) cell lines. In particular, for comparative characterisation of the molecular signatures induced by the combined and mono application, whole transcriptome sequencing was performed. Emphasis was placed on pathways and genes exclusively regulated by drug combinations. Idelalisib + cytostatics combinations changed pathway activation for, e.g., "Retinoblastoma in cancer", "TGF-b signalling", "Cell cycle" and "DNA-damage response" to a greater extent than the two cytostatics alone. Analyses of the top-20 regulated genes revealed that both combinations induce characteristic gene expression changes. A specific set of genes was exclusively deregulated by the drug combinations, matching the combination-specific anti-proliferative cell-biologic effects. The addition of Idelalisib suggests minor synergistic effects which are rather to be classified as additive.
Sections du résumé
BACKGROUND
BACKGROUND
The introduction of combined conventional cytostatics and pathway-specific inhibitors has opened new treatment options for several cancer types including hematologic neoplasia such as leukaemias. As the detailed understanding of the combination-induced molecular effects is often lacking, the identification of combination-induced molecular mechanisms bears significant value for the further development of interventional approaches.
METHODS
METHODS
Combined application of conventional cytostatic agents (cytarabine and dexamethasone) with the PI3K-inhibitor Idelalisib was analysed on cell-biologic parameters in two acute pro-B lymphoblastic leukaemia (B-ALL) cell lines. In particular, for comparative characterisation of the molecular signatures induced by the combined and mono application, whole transcriptome sequencing was performed. Emphasis was placed on pathways and genes exclusively regulated by drug combinations.
RESULTS
RESULTS
Idelalisib + cytostatics combinations changed pathway activation for, e.g., "Retinoblastoma in cancer", "TGF-b signalling", "Cell cycle" and "DNA-damage response" to a greater extent than the two cytostatics alone. Analyses of the top-20 regulated genes revealed that both combinations induce characteristic gene expression changes.
CONCLUSION
CONCLUSIONS
A specific set of genes was exclusively deregulated by the drug combinations, matching the combination-specific anti-proliferative cell-biologic effects. The addition of Idelalisib suggests minor synergistic effects which are rather to be classified as additive.
Identifiants
pubmed: 32817744
doi: 10.1186/s12935-020-01431-4
pii: 1431
pmc: PMC7425054
doi:
Types de publication
Journal Article
Langues
eng
Pagination
390Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Mutat Res. 2009 Mar 9;662(1-2):10-5
pubmed: 19101572
Tumour Biol. 2014 Dec;35(12):12189-200
pubmed: 25179839
Int J Cancer. 2015 Mar 15;136(6):E623-9
pubmed: 25159866
Leukemia. 2007 Apr;21(4):824-7
pubmed: 17268530
PLoS Biol. 2008 Jul 22;6(7):e184
pubmed: 18651794
Cell Death Discov. 2016 Jan 25;2:15070
pubmed: 27551494
Blood. 2017 Jun 1;129(22):3000-3008
pubmed: 28424165
Blood. 2015 Jun 11;125(24):3688-93
pubmed: 25878119
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
J Hematol Oncol. 2017 Jul 28;10(1):145
pubmed: 28754125
Front Oncol. 2018 Feb 15;8:33
pubmed: 29497600
Leukemia. 2014 Apr;28(4):761-9
pubmed: 23958920
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Adv Ther. 2017 Oct;34(10):2232-2273
pubmed: 28983798
Leukemia. 2014 Apr;28(4):739-48
pubmed: 23892718
Biochem Biophys Res Commun. 2012 Dec 14;429(3-4):148-55
pubmed: 23142226
Oncotarget. 2017 Jun 29;8(49):85068-85084
pubmed: 29156704
PLoS Comput Biol. 2011 Dec;7(12):e1002323
pubmed: 22219721
Cancer Res. 2011 Feb 1;71(3):1177-86
pubmed: 21169412
Cell Biosci. 2011 Feb 17;1(1):6
pubmed: 21711675
Sci China Life Sci. 2015 Dec;58(12):1226-32
pubmed: 26566802
Cancer Sci. 2017 Jul;108(7):1476-1484
pubmed: 28418085
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
BMC Cancer. 2010 Oct 15;10:560
pubmed: 20950443
J Exp Clin Cancer Res. 2017 Feb 28;36(1):37
pubmed: 28245840
Nucleic Acids Res. 2005 Mar 30;33(6):1859-73
pubmed: 15800215
J Hematol Oncol. 2017 Aug 14;10(1):148
pubmed: 28806978
N Engl J Med. 2014 Mar 13;370(11):1061-2
pubmed: 24620870
Oncogene. 2010 Mar 18;29(11):1633-40
pubmed: 20010871
Nat Rev Cancer. 2007 Jul;7(7):495-507
pubmed: 17568790
BMC Genomics. 2014 Jun 01;15:416
pubmed: 24885906
Clin J Oncol Nurs. 2016 Dec 1;20(6):E147-E154
pubmed: 27857258
Mol Cancer. 2011 Sep 14;10:113
pubmed: 21917150
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11711-E11720
pubmed: 30487223
Mol Cell Ther. 2015 Mar 20;3:2
pubmed: 26056603
Urol Oncol. 2014 Jan;32(1):53.e23-9
pubmed: 24239460
N Engl J Med. 2014 Mar 13;370(11):1008-18
pubmed: 24450858
Tumour Biol. 2015 Feb;36(2):1251-9
pubmed: 25344677
Oncotarget. 2017 Jun 13;8(24):39033-39047
pubmed: 28380463
Nat Rev Clin Oncol. 2014 Apr;11(4):184-6
pubmed: 24642682
Lancet. 2013 Jun 1;381(9881):1943-55
pubmed: 23523389
Oncoimmunology. 2015 Apr 14;4(8):e1026534
pubmed: 26405587
Anticancer Res. 2012 Feb;32(2):463-74
pubmed: 22287733
Ann Hematol. 2016 Mar;95(4):563-73
pubmed: 26758269
PLoS One. 2016 Sep 09;11(9):e0162638
pubmed: 27611867
Mediterr J Hematol Infect Dis. 2014 Jan 02;6(1):e2014007
pubmed: 24455116
FASEB J. 2013 Oct;27(10):4194-203
pubmed: 23804241
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
J Adv Res. 2014 Nov;5(6):657-61
pubmed: 25685534
Nat Rev Immunol. 2014 Feb;14(2):69-80
pubmed: 24378843
Nucleic Acids Res. 2016 Jan 4;44(D1):D488-94
pubmed: 26481357
Ann Oncol. 2016 Sep;27(suppl 5):v69-v82
pubmed: 27056999
J Exp Med. 2016 Sep 19;213(10):1961-71
pubmed: 27573814
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
PLoS One. 2014 Jan 31;9(1):e85926
pubmed: 24497931
Front Pediatr. 2017 Feb 09;5:4
pubmed: 28232907
Int J Mol Sci. 2019 Jun 15;20(12):
pubmed: 31208040
Asian Pac J Cancer Prev. 2014;15(8):3805-9
pubmed: 24870798
Oncotarget. 2015 May 30;6(15):13105-18
pubmed: 25869207
Blood. 2006 Jun 15;107(12):4589-96
pubmed: 16484590
Am J Health Syst Pharm. 2016 Apr 15;73(8):547-55
pubmed: 26933132